In a clinical trial, pyrotinib also showed promising efficacy, which validated the PDX findings obtained in preclinical testing.165 BTK is a key mediator of BCR-dependent cell growth signaling and a promising therapeutic target for multiple diseases, particularly in hematopoietic malignancies such as MCL. Here, BTK is linked to mantle cell lymphoma.